Brief: Acasti Announces Achievement Of 50% Enrollment In Pivotal Phase 3 Strive-On Safety Trial

Grace Therapeutics

27/06/2024 21:31

Acasti Pharma Inc  ACST.O :
    * ACASTI ANNOUNCES ACHIEVEMENT OF 50% ENROLLMENT IN PIVOTAL
PHASE
3 STRIVE-ON SAFETY TRIAL
    * ACASTI PHARMA INC: ANTICIPATE RANDOMIZING ALL 100 PATIENTS
IN
LATE 2024 TO EARLY 2025
    * ACASTI PHARMA INC:  ANTICIPATE STAYING ON TRACK FOR A
POTENTIAL
NDA SUBMISSION TO FDA IN FIRST HALF OF CALENDAR 2025

Source text for Eikon:  ID:nGNX78cZgX 
Further company coverage:  ACST.O